#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Stress cardiomyopathy Trigeminal neuralgia Epstein-Barr virus infection Kearns-Sayre syndrome Oesophageal adenocarcinoma stage III Mitochondrial myopathy Malignant neoplasm of choroid Acquired haemophilia Rheumatoid arthritis MELAS syndrome Mixed-type liposarcoma Muscular dystrophy Congenital ectodermal dysplasia Drug eruption Amyotrophic lateral sclerosis More trials…

    Learn about Rare Diseases

    Loeys-Dietz syndrome Progressive multifocal leukoencephalopathy – Trials in Disease Ehlers-Danlos syndrome – Basic Information Small intestine leiomyosarcoma – Treatment Paroxysmal nocturnal haemoglobinuria – Life with Disease Systemic sclerosis pulmonary – Life with Disease Sarcoidosis – Basic Information X-linked lymphoproliferative syndrome Fragile X syndrome – Treatment Encephalitis autoimmune – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pd01B Ifezuntirgene Inilparvovec Vimseltinib Indapamide BRENSOCATIB Rly-4008 Jnj-77242113 Rifaximin 6QC-ICG Sodium Butyrate ALE1 Gabapentin Ponesimod Cagrilintide Medi0618 Doxycycline Voxelotor Immunglobulin Nesolicaftor Ethanol (96 Per Cent) More therapies…

    Learn about Your Condition

    Vulvovaginal discomfort Eczema Intestinal ischaemia Mechanical ventilation Psychogenic seizure Anogenital warts Nasopharyngeal cancer Thyroidectomy Glomerulonephritis chronic Porphyria non-acute HER2 negative breast cancer Fibromyalgia Hepatic cirrhosis Hepatitis D Neoplasm malignant More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Antoine Lacassagne

Centre Antoine Lacassagne

33 Avenue De Valombrose, Nice, 06189, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Dostarlimab to Prevent Second Cancer in Patients Cured from Primary Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Dostarlimab
    France

  • Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Cobolimab
    • Docetaxel
    • Dostarlimab
    Belgium Finland France Germany Greece Italy +5

  • A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician’s Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    Investigated Drugs:
    • Doxorubicin Hydrochloride
    • Paclitaxel
    • Sacituzumab Govitecan
    Czechia France Germany Greece Italy Poland +1

  • A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    Belgium Bulgaria Czechia Finland France Germany +6

  • Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabazitaxel
    • Siltuximab
    • Xaluritamig
    Austria Belgium Denmark France Germany Greece +5

  • Study of Tarlatamab alone or with FOLFIRI chemotherapy for patients with advanced digestive system or unknown origin neuroendocrine carcinomas

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Fluorouracil
    • Folinic Acid
    • Irinotecan Hydrochloride Trihydrate
    France Spain

  • Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Zolbetuximab
    • Capecitabine
    • Fluorouracil
    Belgium Czechia France Germany Italy Lithuania +5

  • Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • PUCOTENLIMAB
    France

  • Study on Niraparib and Dostarlimab for Patients with DNA Repair-Deficient or Platinum-Sensitive Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Dostarlimab
    • Niraparib
    France

  • Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abiraterone
    • BMS-986365
    • Docetaxel
    Austria Czechia Denmark France Germany Ireland +6
Previous Page
1 … 13 14 15 16 17 … 28
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!